About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 4NCT02897856

Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures

The goal of this study is to prove that intramuscular midazolam is more effective than buccal midazolam in cessation of seizure activity with comparable side effects.

Lead sponsor: Hamad Medical Corporation•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Hamad Medical Corporation

Both buccal and intramuscular midazolam have been used to control seizures with variable succuss rates and side effects. In this study the investigators are going to assign patient randomly to receive either buccal or intramuscular midazolam. Then will compare both efficacy and side effect in both groups.

Age

0 - 14 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Children 6 month to 14 years who will be presented to the pediatric emergency or attended by emergency medical service who have active seizure and had no intravenous access would be eligible for the study.

Exclusion Criteria

•Cardiac arrest
•Head trauma
•Drowning
•Congenital heart disease
•Inborn errors of metabolism
•Electrolyte imbalance (hypocalcaemia, hyponatremia and hypoglycemia)
•Hemodynamic instability
•Allergy to benzodiazepines
•Focal seizures with preserved level of consciousness

Related studies

RECRUITINGPhase 3

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904 · Stereotypical Prolonged Seizures

RECRUITINGPhase 1/2

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT06388707 · Drug Resistant Epilepsy, Epilepsy, and more

RECRUITINGPhase 2

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

NCT07130786 · Seizures, Primary Motor Cortex, and more

RECRUITINGPhase 3

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142 · Primary Generalized Tonic-Clonic Seizures

RECRUITINGPhase 3

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

NCT07234695 · Down Syndrome, Down Syndrome (DS), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 24, 2019Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment150

Start dateSep 2016

Last updatedJul 24, 2019

Condition

Locations shown

Hamad medical corporation

Doha

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 24, 2019Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions